The Formulation and Delivery of Monoclonal Antibodies

Therapeutic Monoclonal Antibodies: From Bench to Clinic

Volumn , Issue , 2009, Pages 673-709

  Sharma, Vikas K ^a   Chih, Hung Wei ^a   Mrsny, Randall J ^a   Daugherty, Ann L ^a  

^a GENENTECH INC   (United States)

Author keywords

Monoclonal antibody formulation and delivery; Monoclonal antibody formulations strategies and configurations; Novel delivery of monoclonal antibodies

Indexed keywords

EID: 84891038650     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470485408.ch30     Document Type: Chapter

References (217)

1. Al-Abdulla, I., J.M. Garnvwa, S. Rawat, D.S. Smith, J. Landon, and A. Nasidi. 2003. Formulation of a liquid ovine Fab-based antivenom for the treatment of envenomation by the Nigerian carpet viper (Echis ocellatus). Toxicon 42:399-404.
2. Alley, S.C., D.R. Benjamin, S.C. Jeffrey, N.M. Okeley, D.L. Meyer, R.J. Sanderson, and P.D. Senter. 2008. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug. Chem. 19:759-765.
3. Allison, S.D., B. Chang, T.W. Randolph, and J.F. Carpenter. 1999. Hydrogen bonding between sugar and protein is responsible for inhibition of dehydration-induced protein unfolding. Arch. Biochem. Biophys. 365:289-298.
4. Allison, S.D., M.C. Manning, T.W. Randolph, K. Middleton, A. Davis, and J.F. Carpenter. 2000. Optimization of storage stability of lyophilized actin using combinations of disaccharides and dextran. J. Pharm. Sci. 89:199-214.
5. Andya, J., J.L. Cleland, C.C. Hsu, X.M. Lam, D.E. Overcashier, S.J. Shire, J. Yang, and S.S.-Y. Wu. 2001. Protein formulation. U.S. Patent 6,685,940.
6. Andya, J.D., C.C. Hsu, and S.J. Shire. 2003. Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations. AAPS PharmSci. 5, Article 10.
7. Andya, J.D., Y.F. Maa, H.R. Costantino, P.A. Nguyen, N. Dasovich, T.D. Sweeney, C.C. Hsu, and S.J. Shire. 1999. The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody. Pharm. Res. 16:350-358.
8. Andya, J.D., S. Wu, C.C. Hsu, and S.J. Shire. 1996. The effect of sugars and buffer excipients on the stabilization of a lyophilized formulation for an anti-IgE humanized monoclonal antibody. Pharm. Res. 13:S78.
9. Arakawa, T., D. Ejima, K. Tsumoto, N. Obeyama, Y. Tanaka, Y. Kita, and S.N. Timasheff. 2007a. Suppression of protein interactions by arginine: A proposed mechanism of the arginine effects. Biophys. Chem. 127:1-8.
10. Arakawa, T., J.S. Philo, K. Tsumoto, R. Yumioka, and D. Ejima. 2004. Elution of antibodies from a protein-A column by aqueous arginine solutions. Protein Expr. Purif. 36:244-248.
11. Arakawa, T., S.J. Prestrelski, W.C. Kenney, and J.F. Carpenter. 1993. Factors affecting short-term and long-term stabilities of proteins. Adv. Drug Delivery Rev. 10:1-28.
12. Arakawa, T., K. Tsumoto, Y. Kita, B. Chang, and D. Ejima. 2007b. Biotechnology applications of amino acids in protein purification and formulations. Amino Acids 33:587-605.
13. Auton, M., A.C.M. Ferreon, and D.W. Bolen. 2006. Metrics that differentiate the origins of osmolyte effects on protein stability: A test of the surface tension proposal. J. Mol. Biol. 361:983-992.
14. Awdeh, Z.L., B.A. Askonas, and A.R. Williamson. 1967. Homogeneous gamma-G-immunoglobulin produced by mouse plasmacytoma 5563 and its subsequent heterogeneity in serum. Biochem. J. 102:548-553.
15. Baert, F., M. Noman, S. Vermeire, G. Van Assche, D.H.G.A. Carbonez, and P. Rutgeerts. 2003. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348:601-608.
16. Balthasar, S., K. Michaelis, N. Dinauer, H. von Briesen, J. Kreuter, and K. Langer. 2005. Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes. Biomaterials 26:2723-2732.
17. Barbin, K., J. Stieglmaier, D. Saul, K. Stieglmaier, B. Stockmeyer, M. Pfeiffer, P. Lang, and G.H. Fey. 2006. Influence of variable N-glycosylation on the cytolytic potential of chimeric CD19 antibodies. J. Immunother. 29:122-133.
18. Baynes, B.M., D.I.C. Wang, and B.L. Trout. 2005. Role of arginine in the stabilization of proteins against aggregation. Biochemistry (Mosc). 44:4919-4925.
19. Bhatnagar, B.S., R.H. Bogner, and M.J. Pikal. 2007. Protein stability during freezing: Separation of stresses and mechanisms of protein stabilization. Pharm. Dev. Technol. 12:505-523.
20. Bitonti, A.J., J.A. Dumont, S.C. Low, R.T. Peters, K.E. Kropp, V.J. Palombella, J.M. Stattel, Y. Lu, C.A. Tan, J.J. Song, A.M. Garcia, N.E. Simister, G.M. Spiekermann, W.I. Lencer, and R.S. Blumberg. 2004. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc. Natl. Acad. Sci. U.S.A. 101:9763-9768.
21. Bogard, W.C., Jr., R.T. Dean, Y. Deo, R. Fuchs, J.A. Mattis, A.A. McLean, and H.J. Berger. 1989. Practical considerations in the production, purification, and formulation of monoclonal antibodies for immunoscintigraphy and immunotherapy. Semin. Nuclear Med. 19:202-220.
22. Brannon-Peppas, L., and J.O. Blanchette. 2004. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 56:1649-1659.
23. Braun, A., L. Kwee, M.A. Labow, and J. Alsenz. 1997. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm. Res. 14:1472-1478.
24. Breen, E.D., J.G. Curley, D.E. Overcashier, C.C. Hsu, and S.J. Shire. 2001. Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation. Pharm. Res. 18:1345-1353.
25. Brown, W.J., N.R.M. Buist, H.T.C. Gipson, R.K. Huston, and N.G. Kennaway. 1982. Fatal benzyl alcohol poisoning in a neonatal intensive-care unit. Lancet 1:1250.
26. Burris, H.A., I.E. Krop, S. Modi, J. Rodon, S.G. Lutzker, S.N. Holden, S. Bhattacharya, M. Sliwkowski, and M. Beeram. 2006. A phase I study of a first-in-class HER2 antibody-drug conjugate in patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 100:S104.
27. Cacia, J., R. Keck, L.G. Presta, and J. Frenz. 1996. Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: Identification and effect on binding affinity. Biochemistry 35:1897-1903.
28. Cacopardo, B., F. Benanti, G. Brancati, F. Romano, and A. Nunnari. 1998. Leucocyte interferon-alpha retreatment for chronic hepatitis C patients previously intolerant to other interferons. J. Viral Hepat. 5:333-339.
29. Carpenter, J.F., and J.H. Crowe. n.d. An infrared spectroscopic study of the interactions of carbohydrates with dried proteins. Biochemistry (Mosc.) 28:3916-3922.
30. Carpenter, J.F., K. Izutsu, and T.W. Randolph. 1999. Freezing-and drying-induced perturbations of protein structure and mechanisms of protein protection by stabilizing additives. Freeze-Drying/Lyophilization of Pharmaceutical and Biological Products 96:123-160.
31. Carroll, P.V., E.R. Christ, B.A. Bengtsson, L. Carlsson, J.S. Christiansen, D. Clemmons, R. Hintz, K. Ho, Z. Laron, P. Sizonenko, P.H. Sonksen, T. Tanaka, and M. Thorne. 1998. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: A review. J. Clin. Endocrinol. Metab. 83:382-395.
32. Chan, S.Y., A.N. Gordon, R.E. Coleman, J.B. Hall, M.S. Berger, M.L. Sherman, C.B. Eten, and N.J. Finkler. 2003. A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer Immunol. Immunother. 52:243-248.
33. Chang, L.L., D. Shepherd, J. Sun, X.C. Tang, and M.J. Pikal. 2004. Mechanism of protein stabilization by sugars during freeze drying and storage: Specific interaction or matrix effect? J. Pharm. Sci. 94:1427-1444.
34. Chang, L., D. Shepherd, J. Sun, X. Tang, and M.J. Pikal. 2005. Effect of sorbitol and residual moisture on the stability of lyophilized antibodies: Implications for the mechanism of protein stabilization in the solid state. J. Pharm. Sci. 94:1445-1455.
35. Chapman, S.A., K.L. Gilkerson, T.D. Davin, and M.R. Pritzker. 2004. Acute renal failure and intravenous immune globulin: Occurs with sucrose-stabilized, but not with D-sorbitol-stabilized, formulation. Ann. Pharmacother. 38:2059-2067.
36. Chatenoud, L. 2003. CD3-specific antibody-induced active tolerance: From bench to bedside. Nature Rev. Immunol. 3:123-132.
37. Cheifetz, A., and L. Mayer. 2005. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt. Sinai J. Med. 72:250-256.
38. Cheifetz, A., M. Smedley, S. Martin, M. Reiter, G. Leone, L. Mayer, and S. Plevy. 2003. The incidence and management of infusion reactions to infliximab: A large center experience. Am. J. Gastroenterol. 98:1315-1324.
39. Chen, B., R. Bautista, K. Yu, G.A. Zapata, M.G. Mulkerrin, and S.M. Chamow. 2003. Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms. Pharm. Res. 20:1952-1960.
40. Chi, E.Y., S. Krishnan, T.W. Randolph, and J.F. Carpenter. 2003. Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation. Pharm. Res. 20:1325-1336.
41. Chu Grace, C., D. Chelius, G. Xiao, K. Khor Hui, S. Coulibaly, and V. Bondarenko Pavel. 2007. Accumulation of succinimide in a recombinant monoclonal antibody in mildly acidic buffers under elevated temperatures. Pharm. Res. 24:1145-1156.
42. Chung, C.M., J.D. Chiu, L.H. Connors, O. Gursky, A. Lim, A.B. Dykstra, J. Liepnieks, M.D. Benson, C.E. Costello, M. Skinner, and M.T. Walsh. 2005. Thermodynamic stability of a kappa I immunoglobulin light chain: Relevance to multiple myeloma. Biophys. J. 88:4232-4242.
43. Cleland, J.L., X. Lam, B. Kendrick, J. Yang, T.-H. Yang, D. Overcashier, D. Brooks, C. Hsu, and J.F. Carpenter. 2001. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. J. Pharm. Sci. 90:310-321.
44. Cleland, J.L., M.F. Powell, and S.J. Shire. 1993. The development of stable protein formulations: A close look at protein aggregation, deamidation, and oxidation. Crit. Rev. Ther. Drug Carrier Syst. 10:307-377.
45. Colandene, J.D., L.M. Maldonado, A.T. Creagh, J.S. Vrettos, K.G. Goad, and T.M. Spitznagel. 2007. Lyophilization cycle development for a high-concentration monoclonal antibody formulation lacking a crystalline bulking agent. J. Pharm. Sci. 96:1598-1608.
46. Compton, B.J., J.S. Gerald, D.A. Lowe, and R.P. Elander. 1989. Micro isoelectric point heterogeneity of a murine monoclonal antibody (L6) originating from cell cultivation conditions. Biotechnol. Techniques 3:349-354.
47. Cook-Bruns, N. 2001. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 61(Suppl 2):58-66.
48. Costantino, H.R., J.D. Andya, P.A. Nguyen, N. Dasovich, T.D. Sweeney, S.J. Shire, C.C. Hsu, and Y.F. Maa. 1998. Effect of mannitol crystallization on the stability and aerosol performance of a spray-dried pharmaceutical protein, recombinant humanized anti-IgE monoclonal antibody. J. Pharm. Sci. 87:1406-1411.
49. Costantino, H.R., R. Langer, and A.M. Klibanov. 1994. Moisture-induced aggregation of lyophilized insulin. Pharm. Res. 11:21-29.
50. Costantino, H.R., R. Langer, and A.M. Klibanov. 1995. Aggregation of a lyophilized pharmaceutical protein, recombinant human albumin: Effect of moisture and stabilization by excipients. Bio-Technology. 13:493-496.
51. Costantino, H.R., and M.J. Pikal (eds.). 2004. Lyophilization of Biopharmaceuticals. Arlington, VA: American Association of Pharmaceutical Scientists.
52. Crandall, W.V., and L.M. Mackner. 2003. Infusion reactions to infliximab in children and adolescents: Frequency, outcome and a predictive model. Aliment. Pharmacol. Ther. 17:75-84.
53. Crowe, J.H., J.F. Carpenter, and L.M. Crowe. 1998. The role of vitrification in anhydrobiosis. Annu. Rev. Physiol. 60:73-103.
54. Daugherty, A.L., J.L. Cleland, E.M. Duenas, and R.J. Mrsny. 1997. Pharmacological modulation of the tissue response to implanted polylactic-co-glycolic acid microspheres. Eur. J. Pharmacol. Biopharm. 44:89-102.
55. Daugherty, A.L., and R.J. Mrsny. 2006. Formulation and delivery issues for monoclonal antibody therapeutics. Adv. Drug Delivery Rev. 58:686-706.
56. Dick, L.W., C. Kim, D.F. Qiu, and K.C. Cheng. 2007. Determination of the origin of the N-terminal pyro-glutamate variation in monoclonal antibodies using model peptides. Biotechnol. Bioeng. 97:544-553.
57. Dinauer, N., S. Balthasar, C. Weber, J. Kreuter, K. Langer, and H. von Briesen. 2005. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes. Biomaterials 26:5898-5906.
58. Doronina, S.O., B.E. Toki, M.Y. Torgov, B.A. Mendelsohn, C.G. Cerveny, D.F. Chace, R.L. DeBlanc, R.P. Gearing, T.D. Bovee, C.B. Siegall, J.A. Francisco, A.F. Wahl, D.L. Meyer, and P.D. Senter. 2003. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotechnol. 21:778-784.
59. Duddu, S.P., and P.R.D. Monte. 1997. Effect of glass transition temperature on the stability of lyophilized formulations containing a chimeric therapeutic monoclonal antibody. Pharm. Res. 14:591-595.
60. Edelman, G.M., B.A. Cunningham, W.E. Gall, P.D. Gottlieb, U. Rutishauser, and M.J. Waxdal. 1969. The covalent structure of an entire gammaG immunoglobulin molecule. Proc. Natl. Acad. Sci. U.S.A. 63:78-85.
61. Edwards, D.A., J. Hanes, G. Caponetti, J. Hrkach, A. Ben-Jebria, M.L. Eskew, J. Mintzes, D. Deaver, N. Lotan, and R. Langer. 1997. Large porous particles for pulmonary drug delivery. Science 276:1868-1871.
62. Eigenbrot, C.W., J.R. Junutula, H. Lowman, H.E. Raab, and R. Vandlen. 2005. Cysteine engineered antibodies and conjugates. U.S. Patent Application 20070092940.
63. Ejima, D., K. Tsumoto, H. Fukada, R. Yumioka, K. Nagase, T. Arakawa, and J.S. Philo. 2007. Effects of acid exposure on the conformation, stability, and aggregation of monoclonal antibodies. Proteins Struct. Function Bioinformat. 66:954-962.
64. Erickson, H.K., P.U. Park, W.C. Widdison, Y.V. Kovtun, L.M. Garrett, K. Hoffman, R.J. Lutz, V.S. Goldmacher, and W.A. Blattler. 2006. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 66:4426-4433.
65. Frand, A.R., J.W. Cuozzo, and C.A. Kaiser. 2000. Pathways for protein disulphide bond formation. Trends Cell Biol. 10:203-210.
66. Frokjaer, S., and E. Otzen Daniel. 2005. Protein drug stability: A formulation challenge. Nature Rev. Drug Discovery 4:298-306.
67. Gomez, G., M.J. Pikal, and N. Rodriguez-Hornedo. 2001. Effect of initial buffer composition on pH changes during far-from-equilibrium freezing of sodium phosphate buffer solutions. Pharm. Res. 18:90-97.
68. Granholm, A.C., D. Albeck, C. Backman, M. Curtis, T. Ebendal, P. Friden, M. Henry, B. Hoffer, J. Kordower, G.M. Rose, S. Soderstrom, and R.T. Bartus. 1998. A non-invasive system for delivering neural growth factors across the blood-brain barrier: A review. Rev. Neurosci. 9:31-55.
69. Gregory, R.B. 1995. Protein hydration and glass transition behavior. In Protein-Solvent Interactions, ed. R.B. Gregory, 191-264. New York: Marcel Dekker.
70. Griffiths, H.R. 2000. Antioxidants and protein oxidation. Free Radic. Res. 33(Suppl):S47-S58.
71. Griffiths, S.W., and C.L. Cooney. 2002. Relationship between protein structure and methionine oxidation in recombinant human alpha 1-antitrypsin. Biochemistry (Mosc). 41:6245-6252.
72. Gupta, R.K., A.C. Chang, and G.R. Siber. 1998. Biodegradable polymer microspheres as vaccine adjuvants and delivery systems. Dev. Biol. Stand. 92:63-78.
73. Gupta, S., and E. Kaisheva. 2003. Development of a multidose formulation for a humanized monoclonal antibody using experimental design techniques. AAPS J. 5, Article 8.
74. Hancock, B.C., S.L. Shamblin, and G. Zografi. 1995. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm. Res. 12:799-806.
75. Harn, N., C. Allan, C. Oliver, and C.R. Middaugh. 2007. Highly concentrated monoclonal antibody solutions: Direct analysis of physical structure and thermal stability. J. Pharm. Sci. 96:532-546.
76. Harris, R.J. 2005. Heterogeneity of recombinant antibodies: Linking structure to function. Dev. Biologicals 122:117-127.
77. Harris, R.J., B. Kabakoff, F.D. Macchi, F.J. Shen, M. Kwong, J.D. Andya, S.J. Shire, N. Bjork, K. Totpal, and A.B. Chen. 2001. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J. Chromatogr. B Biomed. Sci. Appl. 752:233-245.
78. Hermeling, S., D.J. Crommelin, H. Schellekens, and W. Jiskoot. 2004. Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 21:897-903.
79. Hill, J.J., E.Y. Shalaev, and G. Zografi. 2005. Thermodynamic and dynamic factors involved in the stability of native protein structure in amorphous solids in relation to levels of hydration. J. Pharm. Sci. 94:1636-1667.
80. Holliger, P., and P.J. Hudson. 2005. Engineered antibody fragments and the rise of single domains. Nature Biotechnol. 23:1126-1136.
81. Hooker, A., and D. James. 1998. The glycosylation heterogeneity of recombinant human IFN-gamma. J. Interferon CytokineRes. 18:287-295.
82. Horie, K., N. Horie, A.M. Abdou, J.O. Yang, S.S. Yun, H.N. Chun, C.K. Park, M. Kim, and H. Hatta. 2004. Suppressive effect of functional drinking yogurt containing specific egg yolk immunoglobulin on Helicobacter pylori in humans. J. Dairy Sci. 87:4073-4079.
83. Hovorka, S.W., and C. Schoneich. 2001. Oxidative degradation of pharmaceuticals: Theory, mechanisms and inhibition. J. Pharm. Sci. 90:253-269.
84. w) therapy of refractory/relapsed non-Hodgkin lymphoma. Eur. J. Nuclear Med. Mol. Imaging 34:S168.
85. Imai-Nishiya, H., K. Mori, M. Inoue, M. Wakitani, S. Iida, K. Shitara, and M. Satoh. 2007. Double knockdown of alpha 1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: A new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC. BMC Biotechnol. 7:84 DOI: 10.1186/1472-6750-7-84.
86. Ionescu, R.M., J. Vlasak, C. Price, and M. Kirchmeier. 2008. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J. Pharm. Sci. 97:1414-1426.
87. Izutsu, K., S.O. Ocheda, N. Aoyagi, and S. Kojima. 2004. Effects of sodium tetraborate and boric acid on non-isothermal mannitol crystallization in frozen solutions and freeze-dried solids. Int. J. Pharm. 273:85-93.
88. James, L.C., P. Roversi, and D.S. Tawfik. 2003. Antibody multispecificity mediated by conformational diversity. Science 299:1362-1367.
89. Javed, Q., N. Swanson, H. Vohra, H. Thurston, and A.H. Gershlick. 2002. Tumor necrosis factor-alpha antibody eluting stents reduce vascular smooth muscle cell proliferation in saphenous vein organ culture. Exp. Mol. Pathol. 73:104-111.
90. Jefferis, R. 2002. Glycosylation of recombinant IgG antibodies and its relevance for therapeutic applications (a soupcon of sugar helps the medicine work). Cell Eng. 3:93-107.
91. Jefferis, R. 2005. Glycosylation of recombinant antibody therapeutics. Biotechnol. Prog. 21:11-16.
92. Jespers, L., O. Schon, L.C. James, D. Veprintsev, and G. Winter. 2004. Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold. J. Mol. Biol. 337:893-903.
93. Jiskoot, W., E.C. Beuvery, A.A. de Koning, J.N. Herron, and D.J. Crommelin. 1990. Analytical approaches to the study of monoclonal antibody stability. Pharm. Res. 7:1234-1241.
94. Jones, A.J., S. Putney, O.L. Johnson, and J.L. Cleland. 1997. Recombinant human growth hormone poly(lactic-co-glycolic acid) microsphere formulation development. Adv. Drug Deliv. Rev. 28:71-84.
95. Jones, P.T., P.H. Dear, J. Foote, M.S. Neuberger, and G. Winter. 1986. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature (London) 321:522-525.
96. Kamat, M.S., G.L. Tolman, and J.M. Brown. 1996. Formulation development of an antifibrin monoclonal antibody radiopharmaceutical. Pharm. Biotechnol. 9:343-364.
97. Kawade, Y. 1985. Neutralization of activity of effector protein by monoclonal antibody: Formulation of antibody dose-dependence of neutralization for an equilibrium system of antibody, effector, and its cellular receptor. Immunology 56:497-504.
98. Kendrick, B.S., B.S. Chang, T. Arakawa, B. Peterson, T.W. Randolph, M.C. Manning, and J.F. Carpenter. 1997. Preferential exclusion of sucrose from recombinant interleukin-1 receptor antagonist: Role in restricted conformational mobility and compaction of native state. Proc. Natl. Acad. Sci. U.S.A. 94:11917-11922.
99. Kerwin, B.A., and J.R.L. Remmele. 2007. Protect from light: Photodegradation and protein biologics. J. Pharm. Sci. 96:1468-1479.
100. Kett, V.L., D. McMahon, and K. Ward. 2004. Freeze-drying of protein pharmaceuticals: The application of thermal analysis. Cryoletters 25:389-404.
101. Klareskog, L., M. Gaubitz, V. Rodriguez-Valverde, M. Malaise, M. Dougados, J. Wajdula, and Etanercept Study. 2006. A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 65:1578-1584.
102. Kohler, G., and C. Milstein. 1975. Continuous culture of fused cells secreting antibody of predefined specificity. Nature 256:495-497.
103. Koren, E., L.A. Zuckerman, and A.R. Mire-Sluis. 2002. Immune responses to therapeutic proteins in human: Clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 3:349-360.
104. Kovtun, Y.V., and V.S. Goldmacher. 2007. Cell killing by antibody-drug conjugates. Cancer Lett. 255:232-240.
105. Kroon, D.J., A. Baldwin-Ferro, and P. Lalan. 1992. Identification of sites of degradation in atherapeutic monoclonal antibody by peptide mapping. Pharm. Res. 9:1386-1393.
106. Krop, I.E., M. Beeram, S. Modi, N. Rabbee, S. Girish, J. Tibbitts, S.N. Holden, S.G. Lutzker, and H.A. Burris. 2007. A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with advanced HER2+ breast cancer. Breast Cancer Res Treat. 106:S33.
107. Krotkiewski, H., A. Laskowska, and B. Krotkiewska. 1995. Mouse monoclonal IgA antibodies lack interchain disulfide bonds. Arch. Immunol. Ther. Exp. (Warsz). 43:167-172.
108. Kuo, P.Y., J.K. Sherwood, and W.M. Saltzman. 1998. Topical antibody delivery systems produce sustained levels in mucosal tissue and blood. Nature Biotechnol. 16:163-167.
109. Lackey, C.A., O.W. Press, A.S. Hoffman, and P.S. Stayton. 2002. A biomimetic pH-responsive polymer directs endosomal release and intracellular delivery of an endocytosed antibody complex. Bioconjug. Chem. 13:996-1001.
110. Lam, X., J.Q. Oeswein, B. Ongpipattanakul, Z. Shahrokh, S.X. Wang, R.P. Weissburg, and R.L. Wong. 2000. Stabilized antibody formulation. U.S. Patent 6991790 B1.
111. Lam, X.M., J.Y. Yang, and J.L. Cleland. 1997. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. J. Pharm. Sci. 86:1250-1255.
112. Lavelle, E.C., M.K. Yeh, A.G. Coombes, and S.S. Davis. 1999. The stability and immunogenicity of a protein antigen encapsulated in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol. Vaccine 17:512-529.
113. Lazar, A.C., M.A. Kloczewiak, and I. Mazsaroff. 2004. Matrix-assisted laser desorption/ionization mass spectrometry for the evaluation of the C-terminal lysine distribution of a recombinant monoclonal antibody. Rapid Commun. Mass. Spectrom. 18:239-244.
114. Lechuga-Ballesteros, D., D.P. Miller, and S.P. Duddu. 2004. Thermal analysis of lyophilized pharmaceutical peptide and protein formulations. In Lyophilization of Biopharmaceuticals, ed. H.R. Costantino and M.J. Pikal, 271-336. Arlington, VA: American Association of Pharmaceutical Scientists.
115. Lencer, W.I., and R.S. Blumberg. 2005. A passionate kiss, then run: Exocytosis and recycling of IgG by FcRn. Trends Cell Biol. 15:5-9.
116. Li, B., R.T. Borchardt, E.M. Topp, D. VanderVelde, and R.L. Schowen. 2003. Racemization of an asparagine residue during peptide deamidation. J. Am. Chem. Soc. 125:11486-11487.
117. Li, B., M.H. O'Meara, J.W. Lubach, R.L. Schowen, E.M. Topp, E.J. Munson, and R.T. Borchardt. 2005. Effects of sucrose and mannitol on asparagine deamidation rates of model peptides in solution and in the solid state. J. Pharm. Sci. 94:1723-1735.
118. Li, B., R.L. Schowen, E.M. Topp, and R.T. Borchardt. 2006. Effect of N-1 and N-2 residues on peptide deamidation rate in solution and solid state. AAPS J. 8:E166-E173.
119. Li, G.Q., M.X. Sliwkowski, and G.D.L. Phillips. 2005. Biological activity of trastuzumab-DM1 immunoconjugate in human tumor cells. Clin. Cancer Res. 11:8983S-8983S.
120. Li, S.Q., J.A. Bomser, and Q.H. Zhang. 2005. Effects of pulsed electric fields and heat treatment on stability and secondary structure of bovine immunoglobulin G. J. Agric. Food Chem. 53:663-670.
121. Liao, X.M., R. Krishnamurthy, and R. Suryanarayanan. 2005. Influence of the active pharmaceutical ingredient concentration on the physical state of mannitol-implications in freeze-drying. Pharm Res. 22:1978-1985.
122. Liu, H., G.-G. Bulseco, and J. Sun. 2006. Effect of posttranslational modifications on the thermal stability of a recombinant monoclonal antibody. Immunol. Lett. 106:144-153.
123. Liu, H., G. Gaza-Bulseco, and J. Sun. 2006. Characterization of the stability of a fully human monoclonal IgG after prolonged incubation at elevated temperature. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 837:35-43.
124. Liu, J., M.D.H. Nguyen, J.D. Andya, and S.J. Shire. 2005. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J. Pharm. Sci. 94:1928-1940.
125. Liu, J., and S.J. Shire. 2007. Reduced-viscosity concentrated protein formulations. U.S. Patent Application 20070116700.
126. Luzardo-Alvarez, A., N. Blarer, K. Peter, J.F. Romero, C. Reymond, G. Corradin, and B. Gander. 2005. Biodegradable microspheres alone do not stimulate murine macrophages in vitro, but prolong antigen presentation by macrophages in vitro and stimulate a solid immune response in mice. J. Control. Release 109:62-76.
127. Ma, X., D.Q. Wang, R. Bouffard, and A. MacKenzie. 2001. Characterization of murine monoclonal antibody to tumor necrosis factor (TNF-MAb) formulation for freeze-drying cycle development. Pharm. Res. 18:196-202.
128. Mack, G.S. 2007. Pfizer dumps Exubera. Nature Biotechnol. 25:1331-1332.
129. Mahler, H.C., R. Muller, W. Friess, A. Delille, and S. Matheus. 2005. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eur. J. Pharm. Biopharm. 59:407-417.
130. Marino, M., A. Corti, A. Ippolito, G. Cassani, and G. Fassina. 1997. Effect of bench-scale culture conditions on murine IgGheterogeneity. Biotechnol. Bioeng. 54:17-25.
131. Martsev, S.P., Y.I. Tsybovsky, O.A. Stremovskiy, S.G. Odintsov, T.G. Balandin, P. Arosio, Z.I. Kravchuk, and S.M. Deyev. 2004. Fusion of the antiferritin antibody VL domain to barnase results in enhanced solubility and altered pH stability. Protein Eng. Design Select. 17:85-93.
132. Matheus, S., and H.C. Mahler. 2007. Highly concentrated, liquid formulations of anti-egfr antibodies. U.S. Patent Application 20070172475.
133. Meyer, B.K., A. Ni, B. Hu, and L. Shi. 2007. Antimicrobial preservative use in parenteral products: Past and present. J. Pharm. Sci. 96:3155-3167.
134. Middaugh, C.R., B. Gerber-Jenson, A. Hurvitz, A. Paluszek, C. Scheffel, and G.W. Litman. 1978. Physicochemical characterization of six monoclonal cryoimmunoglobulins: Possible basis for cold-dependent insolubility. Proc. Natl. Acad. Sci. U.S.A. 75:3440-3444.
135. Mine, Y., and J. Kovacs-Nolan. 2002. Chicken egg yolk antibodies as therapeutics in enteric infectious disease: A review. J. Med. Food 5:159-169.
136. Mojica, G., S.M. Hariprasad, R.D. Jager, and W.F. Mieler. 2008. Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration. Br. J. Ophthalmol. 92:584-584.
137. Mordenti, J., K. Thomsen, V. Licko, L. Berleau, J.W. Kahn, R.A. Cuthbertson, E.T. Duenas, A.M. Ryan, C. Schofield, T.W. Berger, Y.G. Meng, and J. Cleland. 1999. Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation. Toxicol. Sci. 52:101-106.
138. Mori, K., S. Iida, N. Yamane-Ohnuki, Y. Kanda, R. Kuni-Kamochi, R. Nakano, H. Imai-Nishiya, A. Okazaki, T. Shinkawa, A. Natsume, R. Niwa, K. Shitara, and M. Satoh. 2007. Non-fucosylated therapeutic antibodies: The next generation of therapeutic antibodies. Cytotechnology. 55:109-114.
139. Morrison, S.L. 2005. The role of glycosylation in engineered antibodies. In Handbook of Carbohydrate Engineering 563-586.
140. Nakamura, T., K.W. Peng, S. Vongpunsawad, M. Harvey, H. Mizuguchi, T. Hayakawa, R. Cattaneo, and S.J. Russell. 2004. Antibody-targeted cell fusion. Nature Biotechnol. 22:331-336.
141. O'Hagan, D.T., D. Rahman, J.P. McGee, H. Jeffery, M.C. Davies, P. Williams, S.S. Davis, and S.J. Challacombe. 1991. Biodegradable microparticles as controlled release antigen delivery systems. Immunology 73:239-242.
142. Oliyai, C., and R.T. Borchardt. 1993. Chemical pathways of peptide degradation. IV. Pathways, kinetics, and mechanism of degradation of an aspartyl residue in a model hexapeptide. Pharm. Res. 10:95-102.
143. w) in inducing and maintaining complete molecular response in B non-Hodgkin's lymphoma patients in clinical complete remission after chemotherapy regimen. Blood 110:196B.
144. Overcashier, D.E., T.W. Patapoff, and C.C. Hsu. 1999. Lyophilization of protein formulations in vials: Investigation of the relationship between resistance to vapor flow during primary drying and small-scale product collapse. J. Pharm. Sci. 88:688-695.
145. Paborji, M., N.L. Pochopin, W.P. Coppola, and J.B. Bogardus. 1994. Chemical and physical stability of chimeric L6, a mouse-human monoclonal-antibody. Pharm. Res. 11:764-771.
146. Page, M., C. Ling, P. Dilger, M. Bentley, T. Forsey, C. Longstaff, and R. Thorpe. 1995. Fragmentation of therapeutic human immunoglobulin preparations. VoxSang. 69:183-194.
147. Park, J.W., C.C. Benz, and F.J. Martin. 2004. Future directions of liposome-and immunoliposome-based cancer therapeutics. Semin. Oncol. 31:196-205.
148. Park, J.W., K. Hong, P. Carter, H. Asgari, L.Y. Guo, G.A. Keller, C. Wirth, R. Shalaby, C. Kotts, W.I. Wood, et al. 1995. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 92:1327-1331.
149. Patel, K., and R.T. Borchardt. 1990. Chemicalpathways of peptide degradation. III. Effect of primary sequence on the pathways of deamidation of asparaginyl residues in hexapeptides. Pharm. Res. 7:787-793.
150. Pavlou, A.K., and M.J. Belsey. 2005. The therapeutic antibodies market to 2008. Eur. J. Pharm. Biopharm. 59:389-396.
151. Perkins, M., R. Theiler, S. Lunte, and M. Jeschke. 2000. Determination of the origin of charge heterogeneity in a murine monoclonal antibody. Pharm. Res. 17:1110-1117.
152. Peterson, N.C. 2005. Advances in monoclonal antibody technology: Genetic engineering of mice, cells and immu-noglobulins. Ilar J. 46:314-319.
153. Pikal, M.J. 1985. Use of laboratory data in freeze-drying process design: Heat and mass transfer coefficients and the computer simulation of freeze-drying. J. Parenter. Sci. Technol. 39:115-139.
154. Pikal, M.J. 1990. Freeze-drying of proteins. II. Formulation selection. BioPharm., October, 26-30.
155. Pikal-Cleland, K.A., J.L. Cleland, T.J. Anchordoquy, and J.F. Carpenter. 2002. Effect of glycine on pH changes and protein stability during freeze-thawing in phosphate buffer systems. J. Pharm. Sci. 91:1969-1979.
156. Poelstra, K.A., N.A. Barekzi, A.M. Rediske, A.G. Felts, J.B. Slunt, and D.W. Grainger. 2002. Prophylactic treatment of gram-positive and gram-negative abdominal implant infections using locally delivered polyclonal antibodies. J. Biomed. Mater. Res. 60:206-215.
157. Polson, A.G., S.C. Lark, C. Du, D. Eaton, K. Elkins, R.N. Fuji, M.A. Go, A. Gray, T. Januario, H. Koeppen, J. Lau, W. Leach, E. McDorman, K. McKeever, S. Prabhu, S.J. Scales, D. Slaga, S. Spencer, M. Williams, D. Xie, S.F. Yu, B. Zheng, and A. Ebens. 2007. Antibody-drug conjugates with uncleavable linkers for the treatment of non-Hodgkin lymphoma. Blood 110:162A.
158. Pyne, A., K. Chatterjee, and R. Suryanarayanan. 2003. Solute crystallization in mannitol-glycine systems: Implications on protein stabilization in freeze-dried formulations. J. Pharm. Sci. 92:2272-2283.
159. Ramsland, P.A., and W. Farrugia. 2002. Crystal structures of human antibodies: A detailed and unfinished tapestry of immunoglobulin gene products. J. Mol. Recognit. 15:248-259.
160. Recchia, F., G. Saggio, A. Cesta, G. Candeloro, A. Di Blasio, G. Amiconi, M. Lombardo, A. Nuzzo, A. Lalli, E. Alesse, S. Necozione, and S. Rea. 2007. Phase II study of interleukin-2 and 13-cis-retinoic acid as maintenance therapy in metastatic colorectal cancer. Cancer Immunol. Immunother. 56:699-708.
161. Reilly, R.M., R. Domingo, and J. Sandhu. 1997. Oral delivery of antibodies. Future pharmacokinetic trends. Clin. Pharmacokinet. 32:313-323.
162. Ressing, M.E., W. Jiskoot, H. Talsma, C.W. Vaningen, E.C. Beuvery, and D.J.A. Crommelin. 1992. The influence of sucrose, dextran, and hydroxypropyl-beta-cyclodextrin as lyoprotectants for a freeze-dried mouse Igg2a monoclonal-antibody (Mn12). Pharm. Res. 9:266-270.
163. Ricart, A.D., and A.W. Tolcher. 2007. Technology Insight: Cytotoxic drug immunoconjugates for cancer therapy. Nature Clin. Practice Oncol. 4:245-255.
164. Robinson, A.B., J.H. McKerrow, and P. Cary. 1970. Controlled deamidation of peptides and proteins: An experimental hazard and a possible biological timer. Proc. Natl. Acad. Sci. U.S.A. 66:753-757.
165. Robinson, N.E. 2002. Protein deamidation. Proc. Natl. Acad. Sci. U.S.A. 99:5283-5288.
166. Robinson, N.E., and A.B. Robinson. 2001. Deamidation of human proteins. Proc. Natl. Acad. Sci. U.S.A. 98:12409-12413.
167. Robinson, N.E., and A.B. Robinson. 2004. Prediction of primary structure deamidation rates of asparaginyl and glutaminyl peptides through steric and catalytic effects. J. Pept. Res. 63:437-448.
168. Rojas, I.A., J.B. Slunt, and D.W. Grainger. 2000. Polyurethane coatings release bioactive antibodies to reduce bacterial adhesion. J. Control. Release 63:175-189.
169. Rothlisberger, D., A. Honegger, and A. Plückthun. 2005. Domain interactions in the Fab fragment: A comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J. Mol. Biol. 347:773-789.
170. Rudikoff, S., A.M. Giusti, W.D. Cook, and M.D. Scharff. 1982. Single amino acid substitution altering antigenbinding specificity. Proc. Natl. Acad. Sci. U.S.A. 79:1979-1983.
171. Saltzman, W.M., J.K. Sherwood, D.R. Adams, P. Castle, and P. Haller. 2000. Long-term vaginal antibody delivery: Delivery systems and biodistribution. Biotechnol. Bioeng. 67:253-264.
172. Saluja, A., A.V. Badkar, D.L. Zeng, and D.S. Kalonia. 2007. Ultrasonic rheology of a monoclonal antibody (IgG(2)) solution: Implications for physical stability of proteins in high concentration formulations. J. Pharm. Sci. 96:3181-3195.
173. Sane, S.U., R. Wong, and C.C. Hsu. 2004. Raman spectroscopic characterization of drying-induced structural changes in a therapeutic antibody: Correlating structural changes with long-term stability. J. Pharm. Sci. 93:1005-1018.
174. Scallon, B.J., S.H. Tam, S.G. McCarthy, A.N. Cal, and T.S. Raju. 2007. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol. Immunol. 44:1524-1534.
175. Schnyder, A., and J. Huwyler. 2005. Drug transport to brain with targeted liposomes. NeuroRx 2:99-107.
176. Schrama, D., R.A. Reisfeld, and J.C. Becker. 2006. Antibody targeted drugs as cancer therapeutics. Nature Rev. Drug Discovery 5:147-159.
177. Schwegman, J.J., L.M. Hardwick, and M.J. Akers. 2005. Practical formulation and process development of freeze-dried products. Pharm. Dev. Technol. 10:151-173.
178. Sgouris, J.T. 1970. Studies on immune serum globulin (IgG) and its modification for intravenous administration. Prog. Immunobiol. Stand. 4:104-113.
179. Sharma, B. 2007. Immunogenicity of therapeutic proteins. II. Impact of container closures. Biotechnol. Adv. 25:318-324.
180. Sharma, V.K., and D.S. Kalonia. 2004. Effect of vacuum drying on protein-mannitol interactions: The physical state of mannitol and protein structure in the dried state. AAPS PharmSciTech. 5:Article 10.
181. Shen, M.Y.K.F.J., R.G. Keck, and R.J. Harris. 1996. The application of tert-butylhydroperoxide oxidation to study sites of potential methionine oxidation in a recombinant antibody. In Techniques in Protein Chemistry, ed. D.R. Marshak, 275-284. Vol. 7, New York: Academic Press.
182. Shire, S.J., Z. Shahrokh, and J. Liu. 2004. Challenges in the development of high protein concentration formulations. J. Pharm. Sci. 93:1390-1402.
183. Spiekermann, G.M., P.W. Finn, E.S. Ward, J. Dumont, B.L. Dickinson, R.S. Blumberg, and W.I. Lencer. 2002. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: Functional expression of FcRn in the mammalian lung. J. Exp. Med. 196:303-310.
184. Street, T.O., D.W. Bolen, and G.D. Rose. 2006. A molecular mechanism for osmolyte-induced protein stability. Proc. Natl. Acad. Sci. U.S.A. 103:13997-14002.
185. Strutzenberger, K., N. Borth, R. Kunert, W. Steinfellner, and H. Katinger. 1999. Changes during subclone development and ageing of human antibody-producing recombinant CHO cells. J. Biotechnol. 69:215-226.
186. Stuart, D.D., G.Y. Kao, and T.M. Allen. 2000. A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1. Cancer Gene Ther. 7:466-475.
187. Sukumar, M., B.L. Doyle, J.L. Combs, and A.H. Pekar. 2004. Opalescent appearance of an IgG1 antibody at high concentrations and its relationship to noncovalent association. Pharm. Res. 21:1087-1093.
188. Szenczi, A., J. Kardos, G.A. Medgyesi, and P. Zavodszky. 2006. The effect of solvent environment on the conformation and stability of human polyclonal IgG in solution. Biologicals 34:5-14.
189. Temming, K., D.L. Meyer, R. Zabinski, P.D. Senter, K. Poelstra, G. Molema, and R.J. Kok. 2007. Improved efficacy alpha(v)beta(6)-targeted albumin conjugates by conjugation of a novel auristatin derivative. Mol. Pharm. 4:686-694.
190. Thirumangalathu, R., S. Krishnan, D.N. Brems, T.W. Randolph, and J.F. Carpenter. 2006. Effects of pH, temperature, and sucrose on benzyl alcohol-induced aggregation of recombinant human granulocyte colony stimulating factor. J. Pharm. Sci. 95:1480-1497.
191. Thomas, J.R., R.C. Yocum, M.F. Haller, and C.F. von Gunten. 2007. Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: The INFUSE-LR study. J. Palliative Med. 10:1312-1320.
192. Tian, W., D. Wong, R. McLaughlin, and D. Pandya. 2006. Mannitol crystallisation in freeze dried dosage forms. J. Pharm. Pharmacol. 58:A23-A24.
193. Tian, W.M., C.L. Zhang, S.P. Hou, X. Yu, F.Z. Cui, Q.Y. Xu, S.L. Sheng, H. Cui, and H.D. Li. 2005. Hyaluronic acid hydrogel as Nogo-66 receptor antibody delivery system for the repairing of injured rat brain: in vitro. J. Control. Release 102:13-22.
194. Tobler, S.A., B.W. Holmes, M.E.M. Cromwell, and E.J. Fernandez. 2004. Benzyl alcohol-induced destabilization of interferon-gamma: A study by hydrogen-deuterium isotope exchange. J. Pharm. Sci. 93:1605-1617.
195. Tuncay, M., S. Calis, H.S. Kas, M.T. Ercan, I. Peksoy, and A.A. Hincal. 2000. In vitro and in vivo evaluation of diclofenac sodium loaded albumin microspheres. J. Microencapsul. 17:145-155.
196. Tyler-Cross, R., and V. Schirch. 1991. Effects of amino acid sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides. J. Biol. Chem. 266:22549-22556.
197. Valente, J.J., K.S. Verma, M.C. Manning, W.W. Wilson, and C.S. Henry. 2005. Second virial coeffcient studies of cosolvent-induced protein self-interaction. Biophys. J. 89:4211-4218.
198. Vidanovic, D., J.M. Askrabic, M. Stankovic, and V. Poprzen. 2003. Effects of nonionic surfactants on the physical stability of immunoglobulin G in aqueous solution during mechanical agitation. Pharmazie 58:399-404.
199. Wakankar, A.A., and R.T. Borchardt. 2006. Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization. J. Pharm. Sci. 95:2321-2336.
200. Wakankar, A.A., R.T. Borchardt, C.E. Eigenbrot, S. Shia, Y.J. Wang, S.J. Shire, and J.L. Liu. 2007a. Aspartate isomerization in the complementarity-determining regions of two closely related monoclonal antibodies. Biochemistry (Mosc). 46:1534-1544.
201. Wakankar, A.A., J. Liu, D. Vandervelde, Y.J. Wang, S.J. Shirem, and R.T. Borchardt. 2007b. The effect of cosolutes on the isomerization of aspartic acid residues and conformational stability in a monoclonal antibody. J. Pharm. Sci. 96:1708-1718.
202. Walsh, S., J. Kokai-Kun, A. Shah, and J. Mond. 2004. Extended nasal residence time of lysostaphin and an anti-staphylococcal monoclonal antibody by delivery in semisolid or polymeric carriers. Pharm. Res. 21:1770-1775.
203. Wang, C.H., K. Sengothi, and T. Lee. 1999. Controlled release of human immunoglobulin G. I. Release kinetics studies. J. Pharm. Sci. 88:215-220.
204. Wang, J., K.M. Chua, and C.H. Wang. 2004. Stabilization and encapsulation of human immunoglobulin G into biodegradable microspheres. J. Colloid Interface Sci. 271:92-101.
205. Wang, W. 1999. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int. J. Pharm. 185:129-188.
206. Wang, W. 2000. Lyophilization and development of solid protein pharmaceuticals. Int. J. Pharm. 203:1-60.
207. Wang, W. 2005. Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm. 289:1-30.
208. Wang, W., S. Singh, D.L. Zeng, K. King, and S. Nema. 2007. Antibody structure, instability, and formulation. J. Pharm. Sci. 96:1-26.
209. Wu, A.M., and P.D. Senter. 2005. Arming antibodies: Prospects and challenges for immunoconjugates. Nature Biotechnol. 23:1137-1146.
210. Xie, G.F., and S.N. Timasheff. 1997a. The thermodynamic mechanism of protein stabilization by trehalose. Biophys. Chem. 64:25-43.
211. Xie, G.F., and S.N. Timasheff. 1997b. Mechanism of the stabilization of ribonuclease A by sorbitol: Preferential hydration is greater for the denatured than for the native protein. Protein Sci. 6:211-221.
212. Xie, M., and R.L. Schowen. 1999. Secondary structure and protein deamidation. J. Pharm. Sci. 88:8-13.
213. Yang, M.X., B. Shenoy, M. Disttler, R. Patel, M. McGrath, S. Pechenov, and A.L. Margolin. 2003. Crystalline monoclonal antibodies for subcutaneous delivery. Proc. Natl. Acad. Sci. U.S.A. 100:6934-6939.
214. Yoshioka, A., K. Fukutake, J. Takamatsu, A. Shirahata, and S. Kogenate. 2006. Post-marketing clinical evaluation of recombinant factor VIII preparation (Kogenate) in previously treated patients with hemophilia A: Descriptive meta-analysis of post-marketing study data. Int. J. Hematol. 84:158-165.
215. Yu, B.L., A. Vizel, M. Young, A. Morando, and B. He. 2007. Impact of degradations on bioactivity: A reflection from a monoclonal antibody. Abstracts of Papers, 234th ACS National Meeting, Boston, MA, August 19-23, 2007:BK>T-136.
216. Zein, N., A.M. Sinha, W.J. McGahren, and G.A. Ellestad. 1988. Calicheamicin-gamma-1-I: An antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 240:1198-1201.
217. Zheng, J.Y., and L.J. Janis. 2006. Influence of pH, buffer species, and storage temperature on physicochemical stability of a humanized monoclonal antibody LA298. Int. J. Pharm. 308:46-51.